The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: A population-based retrospective cohort study

Jung Min Bae, Sung Hye Eun, Sang Ho Oh, Jeong Hyun Shin, Hee Young Kang, Ki Ho Kim, Seung Chul Lee, Chong Won Choi

Research output: Contribution to journalArticle

Abstract

A 308-nm excimer laser (EL) has been widely used to treat patients with localized vitiligo. However, data are rare on the influence of EL treatment on the risks of skin cancer. To evaluate the skin cancer risks after long-term EL treatment, we performed a nationwide population-based retrospective cohort study using the Korean National Health Insurance Claims Database. A total of 5,052 patients with vitiligo were classified into three groups according to the EL treatment sessions between 2009 and 2016: no, 50–99, and 100 or more EL treatments after 2-year washout period (2007 and 2008). Using multivariable Cox proportional hazard models, we found that the risks of actinic keratosis, non-melanoma skin cancers, and melanoma did not significantly differ among the groups, respectively. In conclusion, EL treatment would not increase the risks of premalignant skin lesions and skin cancers in patients with vitiligo. Based on our results, EL is likely to be a safe treatment option for patients with localized vitiligo.

Original languageEnglish
Pages (from-to)714-718
Number of pages5
JournalPigment Cell and Melanoma Research
Volume32
Issue number5
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Excimer Lasers
Vitiligo
Excimer lasers
Skin Neoplasms
Skin
Cohort Studies
Retrospective Studies
Population
Therapeutics
Health insurance
Actinic Keratosis
National Health Programs
Proportional Hazards Models
Melanoma
Hazards
Databases

All Science Journal Classification (ASJC) codes

  • Oncology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Dermatology

Cite this

Bae, Jung Min ; Eun, Sung Hye ; Oh, Sang Ho ; Shin, Jeong Hyun ; Kang, Hee Young ; Kim, Ki Ho ; Lee, Seung Chul ; Choi, Chong Won. / The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo : A population-based retrospective cohort study. In: Pigment Cell and Melanoma Research. 2019 ; Vol. 32, No. 5. pp. 714-718.
@article{29e51974bfe04061b113c7eba976d3c1,
title = "The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: A population-based retrospective cohort study",
abstract = "A 308-nm excimer laser (EL) has been widely used to treat patients with localized vitiligo. However, data are rare on the influence of EL treatment on the risks of skin cancer. To evaluate the skin cancer risks after long-term EL treatment, we performed a nationwide population-based retrospective cohort study using the Korean National Health Insurance Claims Database. A total of 5,052 patients with vitiligo were classified into three groups according to the EL treatment sessions between 2009 and 2016: no, 50–99, and 100 or more EL treatments after 2-year washout period (2007 and 2008). Using multivariable Cox proportional hazard models, we found that the risks of actinic keratosis, non-melanoma skin cancers, and melanoma did not significantly differ among the groups, respectively. In conclusion, EL treatment would not increase the risks of premalignant skin lesions and skin cancers in patients with vitiligo. Based on our results, EL is likely to be a safe treatment option for patients with localized vitiligo.",
author = "Bae, {Jung Min} and Eun, {Sung Hye} and Oh, {Sang Ho} and Shin, {Jeong Hyun} and Kang, {Hee Young} and Kim, {Ki Ho} and Lee, {Seung Chul} and Choi, {Chong Won}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/pcmr.12781",
language = "English",
volume = "32",
pages = "714--718",
journal = "Pigment Cell and Melanoma Research",
issn = "1755-1471",
publisher = "Wiley-Blackwell",
number = "5",

}

The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo : A population-based retrospective cohort study. / Bae, Jung Min; Eun, Sung Hye; Oh, Sang Ho; Shin, Jeong Hyun; Kang, Hee Young; Kim, Ki Ho; Lee, Seung Chul; Choi, Chong Won.

In: Pigment Cell and Melanoma Research, Vol. 32, No. 5, 01.01.2019, p. 714-718.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo

T2 - A population-based retrospective cohort study

AU - Bae, Jung Min

AU - Eun, Sung Hye

AU - Oh, Sang Ho

AU - Shin, Jeong Hyun

AU - Kang, Hee Young

AU - Kim, Ki Ho

AU - Lee, Seung Chul

AU - Choi, Chong Won

PY - 2019/1/1

Y1 - 2019/1/1

N2 - A 308-nm excimer laser (EL) has been widely used to treat patients with localized vitiligo. However, data are rare on the influence of EL treatment on the risks of skin cancer. To evaluate the skin cancer risks after long-term EL treatment, we performed a nationwide population-based retrospective cohort study using the Korean National Health Insurance Claims Database. A total of 5,052 patients with vitiligo were classified into three groups according to the EL treatment sessions between 2009 and 2016: no, 50–99, and 100 or more EL treatments after 2-year washout period (2007 and 2008). Using multivariable Cox proportional hazard models, we found that the risks of actinic keratosis, non-melanoma skin cancers, and melanoma did not significantly differ among the groups, respectively. In conclusion, EL treatment would not increase the risks of premalignant skin lesions and skin cancers in patients with vitiligo. Based on our results, EL is likely to be a safe treatment option for patients with localized vitiligo.

AB - A 308-nm excimer laser (EL) has been widely used to treat patients with localized vitiligo. However, data are rare on the influence of EL treatment on the risks of skin cancer. To evaluate the skin cancer risks after long-term EL treatment, we performed a nationwide population-based retrospective cohort study using the Korean National Health Insurance Claims Database. A total of 5,052 patients with vitiligo were classified into three groups according to the EL treatment sessions between 2009 and 2016: no, 50–99, and 100 or more EL treatments after 2-year washout period (2007 and 2008). Using multivariable Cox proportional hazard models, we found that the risks of actinic keratosis, non-melanoma skin cancers, and melanoma did not significantly differ among the groups, respectively. In conclusion, EL treatment would not increase the risks of premalignant skin lesions and skin cancers in patients with vitiligo. Based on our results, EL is likely to be a safe treatment option for patients with localized vitiligo.

UR - http://www.scopus.com/inward/record.url?scp=85063442609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063442609&partnerID=8YFLogxK

U2 - 10.1111/pcmr.12781

DO - 10.1111/pcmr.12781

M3 - Article

C2 - 30849210

AN - SCOPUS:85063442609

VL - 32

SP - 714

EP - 718

JO - Pigment Cell and Melanoma Research

JF - Pigment Cell and Melanoma Research

SN - 1755-1471

IS - 5

ER -